Furthermore, regorafenib not only enhanced extrinsic and intrinsic apoptosis of bladder cancer cells but also induced the cleavage of PARP1 (Figure 3H), which also demonstrated as an apoptosis marker. Here, PARP1 is linked to urinary bladder carcinoma.